| Hazard Information | Back Directory | [Uses]
Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus[1]. | [in vivo]
Diridavumab (CR6261; 1.7-15 mg/kg; i.p.; BALB/c mice with H2 influenza virus) protects mice against lethal H2 influenza virus in a dose-dependent manner[1]. | Animal Model: | BALB/c mice with H2 influenza virus[1] | | Dosage: | 1.7, 5, or 15 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Prevented mortality and decreased the percent weight loss.
Decreased viral load, altered antigen distribution, and reduced the severity of airway inflammation.
|
| [References]
[1] Sutton TC, et, al. In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice. J Virol. 2017 Nov 30;91(24):e01603-17. DOI:10.1128/JVI.01603-17 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|